Jianmin Pharmaceutical Group Co Ltd - Asset Resilience Ratio
Jianmin Pharmaceutical Group Co Ltd (600976) has an Asset Resilience Ratio of 21.85% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 600976 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2024)
This chart shows how Jianmin Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. See what is Jianmin Pharmaceutical Group Co Ltd's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Jianmin Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Jianmin Pharmaceutical Group Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥947.77 Million | 21.85% |
| Total Liquid Assets | CN¥947.77 Million | 21.85% |
Asset Resilience Insights
- Good Liquidity Position: Jianmin Pharmaceutical Group Co Ltd maintains a healthy 21.85% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Jianmin Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jianmin Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE |
Drug Manufacturers - Specialty & Generic | 1.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 20.24% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Jianmin Pharmaceutical Group Co Ltd (2001–2024)
The table below shows the annual Asset Resilience Ratio data for Jianmin Pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 22.31% | CN¥954.19 Million ≈ $139.63 Million |
CN¥4.28 Billion ≈ $625.95 Million |
+5.64pp |
| 2023-12-31 | 16.66% | CN¥694.46 Million ≈ $101.62 Million |
CN¥4.17 Billion ≈ $609.90 Million |
-2.00pp |
| 2022-12-31 | 18.66% | CN¥641.38 Million ≈ $93.85 Million |
CN¥3.44 Billion ≈ $503.04 Million |
-0.41pp |
| 2021-12-31 | 19.06% | CN¥538.63 Million ≈ $78.82 Million |
CN¥2.83 Billion ≈ $413.47 Million |
-1.04pp |
| 2020-12-31 | 20.10% | CN¥485.79 Million ≈ $71.09 Million |
CN¥2.42 Billion ≈ $353.71 Million |
+2.87pp |
| 2019-12-31 | 17.22% | CN¥332.17 Million ≈ $48.61 Million |
CN¥1.93 Billion ≈ $282.21 Million |
-4.70pp |
| 2018-12-31 | 21.93% | CN¥377.60 Million ≈ $55.25 Million |
CN¥1.72 Billion ≈ $252.01 Million |
+18.60pp |
| 2017-12-31 | 3.33% | CN¥64.00 Million ≈ $9.36 Million |
CN¥1.92 Billion ≈ $281.56 Million |
-8.57pp |
| 2016-12-31 | 11.89% | CN¥215.00 Million ≈ $31.46 Million |
CN¥1.81 Billion ≈ $264.54 Million |
-10.28pp |
| 2015-12-31 | 22.17% | CN¥355.25 Million ≈ $51.98 Million |
CN¥1.60 Billion ≈ $234.43 Million |
+1.49pp |
| 2014-12-31 | 20.69% | CN¥320.00 Million ≈ $46.83 Million |
CN¥1.55 Billion ≈ $226.35 Million |
+20.68pp |
| 2009-12-31 | 0.01% | CN¥74.94K ≈ $10.97K |
CN¥1.30 Billion ≈ $189.66 Million |
+0.00pp |
| 2008-12-31 | 0.00% | CN¥44.58K ≈ $6.52K |
CN¥1.16 Billion ≈ $169.60 Million |
0.00pp |
| 2006-12-31 | 0.00% | CN¥46.00K ≈ $6.73K |
CN¥1.05 Billion ≈ $153.91 Million |
-0.16pp |
| 2005-12-31 | 0.17% | CN¥1.77 Million ≈ $258.68K |
CN¥1.06 Billion ≈ $155.25 Million |
-0.04pp |
| 2004-12-31 | 0.21% | CN¥1.90 Million ≈ $277.46K |
CN¥924.49 Million ≈ $135.28 Million |
+0.14pp |
| 2003-12-31 | 0.07% | CN¥362.79K ≈ $53.09K |
CN¥532.62 Million ≈ $77.94 Million |
+0.05pp |
| 2002-12-31 | 0.02% | CN¥103.62K ≈ $15.16K |
CN¥453.85 Million ≈ $66.41 Million |
-0.01pp |
| 2001-12-31 | 0.03% | CN¥133.86K ≈ $19.59K |
CN¥398.42 Million ≈ $58.30 Million |
-- |
About Jianmin Pharmaceutical Group Co Ltd
Jianmin Pharmaceutical Group Co.,Ltd. manufactures and sells medicines in China. It provides medicines and pediatric drugs under the Jianmin, Longmu, and Yekaitai brand name. The company provides OTC, medical, and general health products, as well as consultation service. Jianmin Pharmaceutical Group Co.,Ltd. was founded in 1993 and is headquartered in Wuhan, China.